{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:24Z","timestamp":1791993924854,"version":"4.4.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T00:00:00Z","timestamp":1431043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0124987","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T14:16:27Z","timestamp":1431094587000},"page":"e0124987","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00701415","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Frits A.","family":"Wijburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Dostalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Fainboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fellgiebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassiano","family":"Forcelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"An Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ronald","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Thurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,5,8]]},"reference":[{"key":"ref1","first-page":"3733","article-title":"The metabolic bases of inherited disease","author":"RJ Desnick","year":"2001"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/18.1.7","article-title":"Enzyme replacement therapy for Fabry disease: proving the clinical benefit","volume":"18","author":"F Breunig","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"CM Eng","year":"2006","journal-title":"Genet Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"WR Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"R Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"S Waldek","year":"2009","journal-title":"Genet Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"M Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"U Ramaswami","year":"2006","journal-title":"Acta Pediatr"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry registry","volume":"64","author":"RJ Hopkin","year":"2008","journal-title":"Pediatr Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"A Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"C Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"C T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease","volume":"13","author":"MC Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"AB Fogo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"C T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"B Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"JE Wraith","year":"2008","journal-title":"J Pediatr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"C T\u00f8ndel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/heart.83.6.667","article-title":"Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe","volume":"83","author":"C Kampmann","year":"2000","journal-title":"Heart"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"TP Roddy","year":"2005","journal-title":"Clin Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"BL Thurberg","year":"2004","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"F Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"GJ Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"BL Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2337\/db07-0019","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy","volume":"56","author":"M Toyoda","year":"2007","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"ref27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000327075","article-title":"Quantitating glomerular endothelial fenestration: an unbiased stereological approach","volume":"33","author":"B Najafian","year":"2011","journal-title":"Am J Nephrol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"E Sch\u00e4fer","year":"2005","journal-title":"Hum Mutat"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","article-title":"Mutation analysis in patients with the typical form of Anderson-Fabry disease","volume":"2","author":"JP Davies","year":"1993","journal-title":"Hum Mol Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/3.3.503","article-title":"Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease","volume":"3","author":"JK Ploos van Amstel","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref31","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"P Ashton-Prolla","year":"2000","journal-title":"J Investig Med"},{"key":"ref32","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"CM Eng","year":"1993","journal-title":"Am J Hum Genet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype","volume":"76","author":"J Shabbeer","year":"2002","journal-title":"Mol Genet Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"B Sachdev","year":"2002","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"J Shabbeer","year":"2006","journal-title":"Hum Genomics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"J Shabbeer","year":"2005","journal-title":"Hum Mutat"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"S Ishii","year":"1992","journal-title":"Hum Genet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype","volume":"46","author":"G Ashley","year":"2001","journal-title":"J Hum Genet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L","article-title":"A sensitive mutation screening for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene","volume":"8","author":"LC Blanch","year":"1996","journal-title":"Hum Mutat"},{"key":"ref40","first-page":"295","article-title":"Gene symbol: GLA","volume":"121","author":"C Spanu","year":"2007","journal-title":"Hum Genet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","article-title":"Functional studies of new GLA gene mutations leading to conformational Fabry disease","volume":"1802","author":"C Filoni","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI118981","article-title":"A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted","volume":"98","author":"N Miyamura","year":"1996","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/hmg\/3.6.1019","article-title":"A nonsense mutation (R220X) in the alpha-galactosidase A gene detected in a female carrier of Fabry disease","volume":"3","author":"C Meaney","year":"1994","journal-title":"Hum Mol Genet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/humu.1219","article-title":"Fabry disease: 20 novel GLA mutations in 35 families","volume":"18","author":"D Blaydon","year":"2001","journal-title":"Hum Mutat"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2009.41.1.001","article-title":"Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease","volume":"41","author":"JY Park","year":"2009","journal-title":"Exp Mol Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"J Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/8904_2011_63","article-title":"Gastrointestinal phenotype of Fabry disease in a patient with pseudoobstruction syndrome","volume":"4","author":"P Buda","year":"2012","journal-title":"JIMD Rep"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"T Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"L van der Tol","year":"2013","journal-title":"J Med Genet"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2215\/CJN.10311110","article-title":"Kidney function reference values in US adolescents: national health and nutrition examination survey 1999\u20132008","volume":"6","author":"BM Chavers","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2215\/CJN.04631007","article-title":"Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients","volume":"3","author":"E Rademacher","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/8904_2011_14","article-title":"Foot process effacement with normal urinalysis in classic Fabry disease","volume":"1","author":"T Kanai","year":"2011","journal-title":"JMID Rep"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement therapy in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"CM Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","article-title":"Fabry disease in children: agalsidase-beta enzyme replacement therapy","volume":"83","author":"L Borgwardt","year":"2013","journal-title":"Clin Genet"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/8904_2013_222","article-title":"Early cardiac changes in children with Anderson-Fabry disease","volume":"11","author":"S Havranek","year":"2013","journal-title":"JIMD Rep"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1477-7525-5-43","article-title":"Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories\/severities utilizing the PedsQL 4.0 Generic Core Scales","volume":"5","author":"JW Varni","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"DP Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"R Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"R Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"M Banikazemi","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0124987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T11:36:24Z","timestamp":1651923384000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0124987"}},"subtitle":[],"editor":[{"given":"Shang-Jyh","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,8]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0124987","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,8]]}}}